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Recent therapeutic successes have renewed interest in drug 
combinations, but experimental screening approaches are 
costly and often identify only small numbers of synergistic 
combinations. The DREAM consortium launched an open 
challenge to foster the development of in silico methods to 
computationally rank 91 compound pairs, from the most 
synergistic to the most antagonistic, based on gene-expression 
profiles of human B cells treated with individual compounds at 
multiple time points and concentrations. Using scoring metrics 
based on experimental dose-response curves, we assessed 32 
methods (31 community-generated approaches and SynGen), 
four of which performed significantly better than random 
guessing. We highlight similarities between the methods. 
Although the accuracy of predictions was not optimal, we 
find that computational prediction of compound-pair activity 
is possible, and that community challenges can be useful to 
advance the field of in silico compound-synergy prediction.
Recent success in the study of synergistic combinations, such as the 
use of CHK1 inhibitors in combination with several DNA damaging 
agents1 or of the PARP inhibitor olaparib in combination with the 
PI3K inhibitor BKM120 (ref. 2), have generated significant interest 
in the systematic screening of compound pairs to identify synergistic 
pairs for combination therapy. Compound synergy can be measured 
by multiple endpoints, including reducing or delaying the devel-
opment of resistance to treatment3 (for instance by abrogating the 
emergence of resistant clones4–6), improving overall survival7,8 or 
lowering toxicity by decreasing individual compound dose9.
Similarly, at the molecular level, synergistic interactions can 
be implemented by several distinct mechanisms. For instance, a 
compound may sensitize cells to another compound by regulating 
its absorption and distribution, modulating the cell’s growth prop-
erties10, inhibiting compound degradation11, inhibiting pathways 
that induce resistance6 or reducing the other compound’s toxicity12. 
When used in combination, two compounds may elicit one of 
three distinct responses: (i) additive, when the combined effect is 
equivalent to the sum of the independent effects; (ii) synergistic, 
when the combined effect is greater than additive; and (iii) antago-
nistic, when the combined effect is smaller than additive. The goal 
of combination therapy is thus to attain a synergistic or at least an 
additive yet complementary effect.
Most approaches to identify synergistic compound pairs are 
still exploratory13,14. In cancer research, synergy assays are usually 
performed by treating cell lines in vitro with all possible compound 
combinations from a diverse library or with candidate combinations 
selected on the basis of mechanistic principles. Unfortunately, such 
experimental screens impose severe limits on the practical size of 
compound diversity libraries. Computational methods to predict 
compound synergy can potentially complement high-throughput 
synergy screens, but the few that have been published lack rigorous 
experimental validation or are appropriate only for compounds that 
modulate well-studied molecular pathways15 or that are equivalent 
to previously established combinations16. Current algorithms are not 
generalizable to arbitrary compound combinations unless molecular 
profile data following compound-pair treatment are available17, which 
is clearly impractical. Thus, there is a need for new methods to predict 
compound synergy from molecular profiles of single compound 
activity, as well as for assays designed to objectively and systematically 
evaluate the accuracy and specificity of such predictions.
To address this issue, the DREAM Challenges initiative (an effort 
run by a community of researchers that poses fundamental ques-
tions in systems biology and translational science in the form of 
a community computational challenge to predict the 
activity of pairs of compounds
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crowdsourced challenges), in collaboration with the National Cancer 
Institute, organized a community-based challenge to systematically 
and objectively test methods to computationally predict compound-
pair activity in human B cells. Challenge participants were asked to 
rank 91 compound pairs (all pairs of 14 compounds) from the most 
synergistic to the most antagonistic in the OCI-LY3 human diffuse 
large B-cell lymphoma (DLBCL) cell line (Fig. 1), based on the gene 
expression profiles of cells perturbed with the individual compounds. 
Predictions were then evaluated against an experimentally assessed 
gold standard, generated by systematic evaluation of compound-pair 
synergy in vitro. This data set was originally intended to experimen-
tally validate the SynGen algorithm, which we introduce for the first 
time in this paper. However, we chose to first give the community 
the opportunity to develop in silico methods for synergy predictions. 
Therefore, we also evaluated SynGen, which, by introducing original 
ideas of synergy prediction, complements the 31 methods that par-
ticipated in the DREAM challenge.
We present a comparative blind-assessment of all 31 methods 
submitted to the DREAM Challenge as well as a nonblind assess-
ment of SynGen. Comparative analyses suggest that some de novo, 
in silico compound synergy prediction methods can achieve a 
performance that is statistically significantly better than random 
guessing. Moreover, integrating the methods can further increase 
performance. Although these results are encouraging, there is still 
much room for performance improvement.
RESULTS
Summary of data set and challenge
Participants were provided with (i) dose-response curves for viability 
of OCI-LY3 cells following perturbation with 14 distinct compounds 
(Supplementary File 1), including DMSO as a control media, (ii) gene 
expression profiles (GEP) in triplicates of the same cells untreated 
(baseline) and at 6 h, 12 h and 24 h following perturbation with each 
of the 14 compounds, and (iii) the previously reported18 baseline 
genetic profile of the OCI-LY3 cell line (Fig. 1). Two compound con-
centrations were used, including the compound’s IC20 (concentra-
tion of drug needed to kill 20% of cells) at 24 h and the compound’s 
IC20 at 48 h, as assessed from nine-point titration curves. Any addi-
tional baseline data from the literature or experimental assays were 
considered admissible in the challenge, but direct measurement of 
compound synergy, even in limited format, was expressly prohibited. 
Challenge participation required ranking each of the 91 compound 
pairs from most synergistic to most antagonistic.
The 31 predictions submitted to this challenge showed considerable 
diversity in the methods and data used (Table 1 and Supplementary 
Table 1). This reflects the lack of standard approaches for predict-
ing compound-pair activity from transcriptomic data and the lack of 
training data (that is, pairs of compounds known to be synergistic or 
nonsynergistic), intentionally preventing use of established machine 
learning methods. Despite broad methodological diversity, of the 31 
teams, 10 based their predictions on the hypothesis that compounds 
with higher transcriptional profile similarity (different similarity 
definitions were used) were more likely to be synergistic (similarity 
hypothesis). In contrast, eight teams assumed the opposite (dissimi-
larity hypothesis). The remaining teams either used a combination 
of similarity and dissimilarity hypotheses (combination hypothesis, 
n = 4) or used more complex hypotheses (n = 9). Only two teams 
made explicit use of OCI-LY3 genetic profiles, suggesting either that 
genomic data are deemed not useful to this analysis or that their use in 
predicting compound synergy is not yet developed. Finally, 12 teams 
relied only on provided information, whereas the others used addi-
tional literature information, such as generic pathway knowledge, 
compound structure or targets, and substrates of these compounds.
Performance evaluation
To objectively evaluate challenge submissions, we generated a 
gold-standard data set based on the experimental assessment of 
OCI-LY3 cell viability for the 91 compound pairs used in the chal-
lenge, at 60 h. The joint compound-pair activity was estimated using 
excess over Bliss (EOB) (Supplementary Fig. 1), which determines 
whether the combined effect of two compounds is significantly greater 
or smaller than the naive (independent) combination of their indi-
vidual effects. These activity estimates were used to rank all pairs from 
most synergistic to most antagonistic (Supplementary Table 2).
Predictions were scored using a modified version of the concord-
ance index19 called the probabilistic concordance-index (PC-index, 
Supplementary Note 1). This metric quantifies the concordance 
between the ranking of compound pairs in the gold standard (Fig. 2a) 
and the predicted ranking in each submission, accounting for 
experimental measurement errors in the estimation of the EOB, 
that is, it estimates the average fraction of compound pairs, over all 
experimental replicates, ranked correctly when rankings of pairs of 
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Figure 1 Overview of data sets used in the  
NCI-DREAM compound-pair activity challenge. 
(a) Gene expression profiles of baseline  
samples, DMSO-treated and 14 single  
compound–treated samples are generated at  
three different time points (6, 12 and 24 h)  
and two different compound concentrations  
(IC20 at 24 and 48 h, where IC20 is defined  
as the compound concentration that kills  
20% of cells). Compound-treated samples  
were generated in triplicate, baseline samples  
in duplicate and DMSO-treated samples in  
octuplicate. (b) The baseline genetic profile of 
the OCI-LY3 cell line obtained previously18 was 
provided to the participants. (c) Participants  
were also provided with the dose-response  
curve following single treatment. The curves  
were derived from a single-agent treatment of  
OCI-LY3 for the indicated time. X represents  
IC20 concentration of a compound. (d) Participants were required to rank each of the 91 pairwise compound combinations of 14 compounds from the  
most synergistic to the most antagonistic. Any additional data derived by participants through analysis of the literature were considered admissible in 
the challenge. Assays to experimentally test compound synergy, even in a limited format, were expressly prohibited.
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compound pairs are compared with their respective experimental 
rank. Other methods such as concordance index or correlation assume 
no ambiguity in the observed ranks. However, experimental noise 
causes uncertainty in ranking compound pairs, thus making these 
methods unsuitable for scoring the predictions. Source code for the 
PC-index can be found in Supplementary Software 1.
Of 31 predictions (SynGen was evaluated separately as it was 
developed by one of the Challenge organizers and therefore it 
Table 1 Summary of methods and data used by each participant
Rank PC-index Summary
Data type 
used
Similarity in compound activity leads to synergy
2a 0.60518 Identified a set of core genes defined by statistically significant DEGs in at least one compound treatment and used these genes  
to estimate interaction score by calculating number of overlapping genes, taking direction of regulation into account.
GD
4a 0.57529 Computed a Pearson correlation between gene expression profiles of two compounds using genes DEGs in at least one  
compound treatment.
G
7a 0.56219 Used support vector machine, trained using chemical properties, chemogenomic profiling and gene-expression data of a set of 
synergistic fungicidal compounds13.
GA
8a 0.5507 Designed a scoring function that combines target and transporter information of each compound, DEGs, their t-score and the 
number of common DEGs between two compounds38,39.
GDA
9a 0.5327 Used the rank-aggregation method to combine results obtained from compound-pair similarity using correlation, common  
compound affected pathways, set of common compound-gene interactions ( from ChEMBL), compound-genes interaction for  
one compound that are significantly affected by other compounds and compound pairs in the same clinical trial40,41.
GPDA
11a 0.52848 Determined cell viability by predicting activation of biological pathways in response to a single compound treatment and  
combined this with dose-response curves42.
GPD
12a 0.52779 Used score combining overlap of gene expression signatures of individual compound treatments and cell line-specific signature 
derived from external datasets, taking direction of regulation into account.
GA
14a 0.51854 Constructed probable pathways connecting compound targets and DEGs and used the Jaccard score based on gene co-occurrences 
in these pathways.
GPA
15a 0.51624 Used weighted Euclidean distance, weighted by activity of each compound. GD
31a 0.41993 Computed correlation between gene expression profiles of two compounds using genes DEGs in at least one compound treatment. G
Dissimilarity in compound activity leads to synergy
5a 0.56637 Computed the Manhattan distance between pathways significantly enriched by each compound. GP
6a 0.56495 Designed a geometric-based score using the number of significant DEGs, the number of common DEGs between two compounds, 
the correlation between their gene expression profile and the dose-response curve.
GD
18a 0.50653 Applied the Pareto ranking strategy using compound activity as well as chemical and target similarity43. GA
19a 0.50501 Built a model that measures the effect on each of the 15 core signaling pathways by considering the number of significant DEGs, 
the number of common DEGs between two compounds and the direction of regulation.
GP
20a 0.49602 Built a cooperative score by combining the number of significant DEGs, the number of common DEGs between two compounds 
and the correlation between weighted gene expression profiles.
G
24a 0.46791 Identified a set of core genes defined by statistically significant DEGs in at least one compound treatment and used these genes  
to estimate interaction score by calculating the number of overlapping genes, taking direction of regulation into account.
G
25a 0.45415 Estimated deviation between correlation using gene expression profile and correlation using GO terms enriched by two compounds 
and used that as a measure of synergy.
GP
26a 0.44467 Built a model combining the IC20 concentration of two compounds and the correlation between their gene expression profiles. G
Combination of similarity and dissimilarity in compound activity leads to synergy
1a 0.61303 Drug Induced Genomic Residual Effect (DIGRE) model (see main text). GPDA
3a 0.59981 Drug Induced Genomic Residual Effect (DIGRE) model (see main text; different cut-off for feature selection). GPDA
21a 0.48988 Estimated the similarity between compound pairs using DEG’s and pathway information and combined this similarity with  
dose-response curves.
GPDA
29a 0.42992 Linear interpolation between two dose points on dose-response curve using similarity between each compound pair, calculated  
by overlap of DEGs.
GPDA
Complex synergistic relationship
10a 0.52974 Used expression of genes, identified from the public dataset whose expression are correlated with overall survival, to predict cell 
viability.
GDA
13a 0.51952 Used OCI-LY3 virtual baseline created from The Cellworks proprietary Tumor Cell Technology, trained using the known mode of 
actions of the compounds44.
GPDA
16a 0.50927 Built a model linking gene expression and cell viability. Used predicted gene expression profile after a compound combination in 
this model to infer the cell viability of compound pairs.
GD
17 0.50703 Identified potential effective targets by comparing expression profiles of effective and ineffective compounds and computed the 
sum of log-odd ratio for each compound pair under the naïve Bayes assumption.
G
22a 0.48568 Built a bagged regression trees model using features obtained from known synergistic and antagonistic compound pairs from  
published literature45.
NA
23a 0.47183 Used expression of genes, identified from the public dataset whose expression are correlated with overall survival, to predict cell 
viability.
GDA
27a 0.44346 Used the Bayesian estimation of temporal regulation and the nearest template prediction algorithm with cosine distance to  
associate significantly DEGs between pairs of drugs46.
GD
28a 0.43479 Predicted expression profile after the treatment with 2 compounds using ANOVA based liner regression and built a model  
linking gene expression and cell viability.
GD
30 0.42297 Used model trained using target and chemical structure of known compound combinations in cancer therapy along with  
protein-protein interactions.
GPA
All methods are categorized into four groups based on distinct hypotheses used by various teams. G, gene expression profile; A, additional information not provided in the  
challenge; D, dose-response curve; P, pathway.
aDetailed method description is available in the Supplementary Note 2. The summary reported in this table was obtained directly from the participants.
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did not participate in the Challenge on the same terms as the other 
31 methods), three methods (DIGRE, IUPUI_CCBB and DPST) 
produced predictions that were statistically significant at a con-
servative false-discovery rate threshold (FDR = 0.05) (Fig. 2b). 
Independent of whether these methods may help in planning large 
synergy screens, this suggests that compound synergy prediction is 
possible. Furthermore, our challenge-based blind assessment of these 
methods’ performance provides a realistic and effective baseline for 
further methodological development.
We found little obvious association between method performance 
and data utilization (Fig. 2b and Supplementary Fig. 2). Only use of 
gene expression profiles at 24 h following treatment showed a minimal 
effect on performance (Supplementary Fig. 2). However, this trend 
was not statistically significant and additional data will be required 
to evaluate it. Additionally, distinct hypotheses used by the teams 
may have had an influence on performance (Supplementary Fig. 3  
and Table 1). For instance, teams using similarity or combination 
hypotheses achieved overall a higher PC-index compared to other 
teams using other hypotheses. However, these differences are not 
statistically significant and are reported here for completeness.
To test performance consistency, we scored each prediction using 
a second metric (resampled Spearman correlation). Both metrics 
yielded virtually identical performance evaluation (correlation 
r = 0.99), with only small differences in rank for a few methods 
that did not perform better than random (Supplementary Fig. 4). 
The robustness of the prediction ranking was tested by removing one 
compound at a time from the set and considering the remaining 13 
compounds (leave-one-out). This analysis revealed that the predic-
tions from two best-performing methods consistently ranked in the 
top 5 across each of the 14 different rankings obtained by removing 
each compound, suggesting that their predictions are only weakly 
biased by any specific drug selection (Fig. 2c and Supplementary 
Fig. 5). The remaining methods showed much greater variation in 
their performance.
Best performing methods
The best performing method, DIGRE (drug-induced genomic resid-
ual effect) hypothesizes that when cells are sequentially treated with 
two compounds, the transcriptional changes induced by the first con-
tribute to the effect of the second (Fig. 3a). This is consistent with the 
observation that sequential drug administration affects outcome20,21. 
Thus, although compounds were administered simultaneously in 
the experimental assays, the algorithm models synergy sequentially. 
DIGRE implements three major steps. The first step involves compar-
ing transcriptional changes following individual compound treatment 
to derive a compound-pair similarity score. This is obtained, first, by 
overlapping differentially expressed genes after treatment with the two 
compounds with eight cell growth–related KEGG pathways (focused 
view), and second, by considering genes upstream of the differentially 
expressed genes in 32 cancer-relevant KEGG pathways (global view). 
In the second step, the effects of compound-induced transcriptional 
changes on cell survival are approximated using a compound similar-
ity score r, defined as: (1 − fB+A′) = (1 − rf2B)[1 − (1 − r)fB], assuming 
that samples were treated first with compound A (where ′ suggested 
primary treatment) followed by compound B (Fig. 3b). Here, fB+A′ 
represents the cell viability reduction after B treatment, following the 
transcriptional changes induced by A, r is the compound-pair similar-
ity score, fB is the viability reduction after B treatment, and f2B is the 
viability reduction for a double dose of B, estimated from the dose-
response curve. The final step introduces a combined score defined 
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Figure 2 Gold standard data for evaluation and performance of predictions. (a) The results of excess over Bliss for all compound pairs ranked from  
most synergistic to most antagonistic. Error bars represent the s.e.m. of excess over Bliss, estimated from five experimental replicates. The solid  
gray line at excess over Bliss equals 0 and represents a line over and below which compound pairs are generally considered synergistic and antagonistic, 
respectively. (b) PC-index for all participants grouped by the kind of data or information used by their method. There is no apparent correlation 
between the final score with the kind of data or information used. AI, additional information other than pathway information used; DRC, dose-response 
curve used; GEP, gene expression profile used; PW, pathway information used. The rank of each team is reported on the top of the bar. The gray line 
represents random performance. The y axis on right shows the PC-indexnorm where PC-index is normalized to have a score between 0 and 1.  
*FDR ≤ 0.20; **FDR ≤ 0.05. (c) Box plot showing the median, quartile and range of ranks for each team in leave-one-out test. All teams are sorted  
by their PC-index. Teams are color coded with the kind of data or information used by their methods.
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as ZB+A′ = 1 − (1 − fA)(1 − fB+A′), where fA is the viability reduction 
after A treatment. Finally, the fraction of dead cells Z, also defined as 
synergistic score, is estimated as the average between the two possible 
sequential orders of treatment (Supplementary Note 2).
Our analyses suggest that the following factors contribute to DIGRE 
performance (Fig. 3c): (i) the hypothesis that compound synergy is 
at least partially due to compound-induced transcriptomic residual 
effects, which are the transcriptional changes induced by the first com-
pound that contribute to the cell inhibition effect of both compounds; 
(ii) using explicit mathematical models to quantify the relationships 
between transcriptomic changes and compound synergy (i.e., analysis 
of compound-induced transcriptomic residual effects and compound 
similarity score); (iii) using information from the full dose-response 
curve instead of just the IC20 data; (iv) incorporating pathway infor-
mation (focused view) and gene-gene interactions (global view) to 
measure similarity between transcriptomic changes induced by dif-
ferent compounds; and (v) using external data sets to optimize path-
way selection and model parameters. When each of these factors was 
systematically removed from the analysis, the algorithm performance 
decreased. In particular, the residual effect hypothesis is critical as 
its removal completely abrogates the algorithm’s predictive power 
(Supplementary Note 2 and Supplementary Fig. 6).
The second-best-performing method (IUPUI_CCBB) hypothesized 
that the activity of a compound can be estimated from its effect on the 
genes that are significantly differentially expressed following treat-
ment with highly toxic compounds versus control media. Compound 
synergy or antagonism is then determined by computing whether the 
effect of two compounds on this set of genes is concordant or discord-
ant, by means of a compound-pair interaction score.
For methods that are not based on machine learning and can-
not thus rely on positive and negative examples, performance is 
determined by how well they model the underlying biology of the 
process. As such, the best-performing algorithms exploited the dose-
response curve, the concept that one compound may have a faster 
pharmacodynamics than the other, and also the fact that synergy was 
estimated by excess over Bliss additivity. Further information about 
all participating methods and the source codes for the DIGRE and 
IUPUI_CCBB methods can be found in Supplementary Note 2  
and Supplementary Software 2 and 3.
Community-based methods
Participants used quite distinct computational strategies resulting 
in at least partially statistically independent predictions that may be 
complementary. This suggests that their integration may outperform 
individual methods. Similar integrative methods have been successful 
in a variety of biological challenges, such as predicting the disorder 
of proteins22, identifying monoamine oxidase inhibitors23, inferring 
gene regulation24, and in cancer prognostics25 and diagnostics26.
To test the predictive power of integrative approaches, we divided 
the gold standard data set into three subsets (S1, S2 and S3). S1 was 
used to sort the methods from best to worst performers, S2 for deter-
mining how many of the top-performing methods should be inte-
grated to achieve optimal performance, and S3 for determining the 
final performance of the best individual and best integrative methods 
independent of training bias, thus avoiding overfitting. This provides a 
practical approach to implement multimethod integration as a crowd-
sourcing activity. Based on 1,000 distinct S1, S2 and S3 splits, we found 
that integrative methods consistently and significantly outperformed 
the best single methods obtained from S1 (P ≤ 10−36, by Wilcoxon 
rank sum test, Fig. 4a) in more than 75% of splits (Supplementary 
Fig. 7). When using only single best method’s performance (ordered 
according to set S1), average integrative performance (when evaluated 
independently in both set S2 and S3) peaked at ~7% improvement, 
when the first seven methods were integrated, and decreased mono-
tonically when more than seven methods were used (Fig. 4b). When 
also selecting the optimal number of methods (based on evaluations 
in S2), integration of the first 4–6 methods, on average, produced the 
best result (Supplementary Fig. 8). Critically, challenge submissions 
were evaluated using the full 91 compound-pair set, whereas predic-
tive power of the crowdsourcing approach was evaluated using only a 
third of these (i.e., 30 compound pairs). This consideration should be 
taken into account when comparing the PC-index in Figures 2b and 4. 
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Figure 3 The DIGRE model. (a) Biological hypotheses of the DIGRE model submitted by the best-performing team. The combined compound effect 
for compounds A and B is hypothesized to result from the compound-induced genomic residual effect. If cells were treated by compounds A and 
B sequentially, the genomic changes induced by compound A will further contribute to the effect induced by compound B. Here, fX denotes the 
percentage of cells killed by compound X and fB+A′ represents the cell viability reduction after B treatment, following the transcriptional changes 
induced by A. Based on this hypothesis, the estimation of the combinatorial compound effect (ZB+A′) reduces to the estimation of the compound-
induced genomic residual effect (fB+A′) (Supplementary Note 2). (b) Workflow of DIGRE. (Step 1) The genomic or transcriptome changes induced  
by two compounds are compared. The similarity score is refined by using pathway information and an external training data set. (Step 2)  
A mathematical model incorporates the similarity score and the dose-response curves to estimate the compound-induced genomic residual effect.  
(Step 3) A combined score is estimated for each of the two possible sequential orders of treatment and finally the synergistic score is estimated as  
the average combined score obtained by two possible sequential orders of treatment. (c) Key ingredients of the DIGRE model.
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Such an increase in performance when integrating disparate methods 
has been called the “wisdom of crowds”24.
Methods’ advantages and limitations
Because multimetric evaluation provides a broader assessment of a 
method’s bias and value27, we used two additional metrics, sensitivity 
versus specificity (ROC) analysis and precision/sensitivity analysis, for 
performance assessment. The first is a threshold-free metric designed 
to assess a method’s tradeoff between sensitivity and specificity in pre-
dicting synergistic or antagonistic combinations, whereas the second 
tests how precise in predicting the intended pairs the methods are at 
a specific cutoff. If we choose the cutoff to be the number of pairs 
of interest (that is, the number of synergistic and antagonistic pairs 
when studying synergy and antagonism, respectively), then precision 
coincides with sensitivity.
We first defined a criterion and identified 16 synergistic and 36 
antagonistic compound pairs (Fig. 5a). We then evaluated the sen-
sitivity versus specificity tradeoff using the area under the receiver 
operating characteristic (ROC) curve (AUC)28 independently for syn-
ergistic and antagonistic compound pairs (Supplementary Fig. 9), 
resulting in distinct rankings. Based on AUC ranking, DIGRE was 
the best algorithm for antagonistic pair prediction and the fourth 
for synergistic ones. Conversely, the second team was the best per-
former in predicting synergistic pairs but did not perform well on 
antagonistic ones (Fig. 5b). Using the ROCs, we could also compute 
the statistical significance of the difference in performance of any 
two methods using the Hanley-McNeil method. This was done sepa-
rately for synergistic and antagonistic compound pairs. We considered 
method A to outperform method B if its ROC-based performance was 
statistically significantly better, either in predicting antagonism or 
synergy (P ≤ 0.05). This analysis revealed no statistically significant 
differences in the direct performance comparison of the top methods 
(Supplementary Fig. 10) but confirmed that the top three methods 
were statistically significantly better than the others.
We performed precision/sensitivity analysis by selecting the top 16 
and the bottom 36 predictions from each method (Online Methods). 
Using this metric, the fifth overall best method and DIGRE were the 
best at predicting synergistic and antagonistic combinations, respec-
tively (Fig. 5c). When a similar analysis was performed to test for the 
misclassification rate (i.e., synergistic pairs predicted as antagonistic 
and vice versa), we found that DIGRE’s misclassification rate was very 
low, despite their weak performance in predicting synergistic pairs 
(Supplementary Fig. 11); that is, although the algorithm was not 
effective at identifying synergistic pairs, it virtually never misclassified 
a synergistic pair as antagonistic and vice versa (they were misclassi-
fied as additive). Across these metrics, the methods’ hypotheses had 
a trending effect on predicting synergy (methods using a similarity 
hypothesis trended to have better sensitivity, Supplementary Fig. 12a) 
based on precision/sensitivity analysis but hardly any effect on 
predicting antagonism (Supplementary Fig. 12b), suggesting that 
hypotheses needed to correctly predict synergy and antagonism may 
be different. We need more extensive studies to confirm if such a 
trend generalizes.
As we did for the PC-index, we also evaluated the performance 
of aggregating predictions by various methods using these metrics 
to test “wisdom of crowds.” Due to the limited number of synergis-
tic (16) and antagonistic (36) compound pairs, we could not divide 
the gold standard data set into three subsets (S1, S2 and S3) to train 
and evaluate the performance of aggregating predictions by various 
methods on these metrics. Therefore, we used the training outcome 
based on the PC-index used in the previous section and averaged the 
performance of the optimized number of top-performing methods 
according to S2 across 1,000 partitions to determine the average pre-
cision and AUC metrics to test “wisdom of crowds.” Similar to the 
PC-index, average integrated performance of the top seven methods 
(when evaluated in S3) showed 14% and 7% improvement in AUC for 
predicting synergistic and antagonistic compound pairs, respectively, 
compared to only single-best method’s performance (ordered accord-
ing to set S1). Results showed that “wisdom of crowds” results in high 
and consistent performance across all metrics, further supporting 
the notion of integrative strategies in scientific research. Indeed, no 
individual method outperformed the others across all metrics, sug-
gesting that multiple hypotheses may need to be combined to globally 
address context-dependent compound synergy and antagonism. In 
particular, although several methods (Fig. 5c) were clearly statisti-
cally significant in predicting compound synergy, overall sensitivity 
was relatively modest (the highest being 37.5% (P ≤ 0.02), compared 
to 17.6% by random selection, Fig. 5c). Performance using “wisdom 
of crowds” did especially well, achieving greater than 46% sensitiv-
ity for synergy and 51% for antagonism, suggesting that methods 
for in silico assessment of compound synergy are starting to achieve 
predictive value.
The SynGen algorithm
The experimental data set was originally intended to validate SynGen, 
a method explicitly designed to predict synergy and not antagonism. 
Following on results from several publications6,29–33, SynGen assumes 
that the activity of the Master Regulators (MRs) of a specific cellular 
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phenotype, as inferred by the Master Regulator Inference algorithm 
MARINa29,30, is essential for cell viability (akin to oncogene addic-
tion34). MRs are defined as regulators that are causally necessary and 
sufficient for the maintenance of a phenotype-specific gene expres-
sion signature. Thus, perturbations that either (i) abrogate the activity 
pattern of cell state MRs or (ii) activate MRs of cell death pheno-
types, as also inferred by MARINa, may induce loss of cell viability. 
Based on this hypothesis, SynGen first infers relevant MR patterns 
for OCI-LY3 cell death and cell state and then identifies compounds 
that are most complementary in inducing the former and abrogat-
ing the latter (Supplementary Note 2). Two signatures used for MR 
inference were (i) a ‘cell death’ signature based on GEP following 
perturbation by the 14 compounds at 24 h, which induce appreciable 
toxicity levels (IC20); and (ii) a ‘cell addiction’ signature, associated 
with the activated B-cell subtype of DLBCL cells (which include 
OCI-LY3) versus germinal center B-cell subtype, as we have shown 
that MRs of tumor subtype elicit addiction30. The latter signature was 
computed using publically available GEPs35 for germinal center B-cell 
subtype cell lines (OCI-LY1, OCI-LY7, OCI-LY8, OCI-LY18 and 
SUDHL5) and for the activated B-cell subtype line OCI-LY3. SynGen 
then predicted synergistic compound combinations by selecting 
the compound pairs that are most complementary in implementing 
or abrogating these MR patterns, respectively. SynGen predicted 
synergistic compound pairs with high sensitivity (56%, P ≤ 0.001). 
However, its ability to predict the full compound-pair ranking was not 
statistically significant, as the algorithm was not designed to predict 
compound antagonism. Source code for the SynGen algorithm can 
be found in Supplementary Software 4.
Compound- and cell-dependent bias
To analyze whether specific compound categories are more 
likely to elicit synergy or antagonism, and whether successful 
predictions were biased toward specific compounds, we ranked 
all compounds using the area under recall curve, AURC, for their 
specific combinations (Supplementary Fig. 13). High AURCs 
indicate compound proclivity toward synergy, whereas low AURCs 
indicate antagonism. Analysis of gold standard data suggests that 
pleiotropic compounds, exhibiting significant polypharmacology, 
such as H-7 and mitomycin C, were enriched in synergistic pairs. 
Conversely, compounds with more targeted mechanisms, such as 
rapamycin and blebbistatin, were least synergistic.
Finally, to determine whether synergy or antagonism is a uni-
versal property of the compound pairs or is context specific, we 
performed additional experiments to assess synergistic activity 
for 142 compound pairs in MCF7 breast cancer cells and LNCaP 
prostate cancer cells and compared them (Supplementary Table 3). 
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antagonistic. (b) Area under the ROC (AUC) for 
synergistic (red) and antagonistic (blue) compound 
pairs. Teams are ranked by their performance in the 
challenge. WoC, performance of the “wisdom  
of crowds.” Black horizontal dashed line shows  
the average performance of random predictions. 
*FDR ≤ 0.20; **FDR ≤ 0.05. (c) Precision and 
sensitivity for synergistic (red) and antagonistic 
(blue) compound pairs. Horizontal dashed line 
in red and blue shows random performance for 
synergistic and antagonistic compound pairs, 
respectively. WoC, performance of the “wisdom of 
crowds.” Teams are ranked by their performance in 
the challenge. *P ≤ 0.05; **FDR ≤ 0.20.
np
g
© 
20
14
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
1220 VOLUME 32 NUMBER 12 DECEMBER 2014   nature biotechnology
a n a ly s i s
The analysis revealed no significant correlation between compound 
pairs ranked from the most synergistic to the most antagonistic (ρ = –0.06, 
P = 0.45, Supplementary Fig. 14). This shows that synergy and 
antagonism are highly context specific and are thus not universal 
properties of the compounds’ chemical, structural or substrate infor-
mation. As a result, predictive methods that account for the genetics 
and regulatory architecture of the context will become increasingly 
relevant to generalize results across multiple contexts.
DISCUSSION
This challenge provides a systematic and comparative evaluation of 
compound synergy and antagonism prediction methods based on 
blind experimental data. There are at least four reasons supporting 
the value and significance of this effort. First, although there are 
no previous experimentally validated efforts to predict synergy or 
antagonism of arbitrary compound pairs from single-compound 
perturbation data, our analysis shows that several laboratories 
have developed methodologies whose predictive ability is signifi-
cantly better than random. Second, synergy and antagonism emerge 
as strongly context-dependent compound-pair properties. Thus, 
the value of synergy prediction methods is even more relevant, as 
experimental high-throughput synergy screen results cannot be 
generalized from one cellular context to others. Third, despite a 
complete lack of publications and established methodologies in 
this area, 31 teams from more than 13 countries participated in the 
challenge, thus effectively creating major interest in this field that 
over the long run is likely to further enhance our abilities to predict 
compound synergy and antagonism. Fourth, we established rigor-
ous evaluation metrics for the assessment of synergy and antago-
nism prediction methods, thus allowing identification of three 
individual methods whose predictions significantly outperformed 
random guessing.
Although it is premature to claim that these advances will have an 
immediate and dramatic impact on the design of high-throughput 
screening assays for compound synergy assessment, the top-performing 
methods identified by this challenge already provide substantial 
potential reductions of the search space, suggesting that further 
improvements may increase the practical value of these techniques. 
For instance, the best-performing synergy-prediction method 
would have allowed screening only half of the compound com-
binations without missing any synergistic pair (Supplementary 
Fig. 15). Furthermore, many large-scale data sets representing 
individual compound perturbations are being generated and put in the 
public domain, such as those generated by the Library of Integrated 
Network-based Cellular Signatures (LINCS), which produced 
over 300,000 gene expression profiles following single-compound 
perturbations across multiple cell lines. It is reasonable to expect 
that availability of these data sets will lead to additional advances in 
the predictive power of these methods.
Introduction of additional, more specific metrics suggests that 
different methods did not score consistently across all of them, and 
that none of the methods is effective in predicting both synergy and 
antagonism. This suggests that the specific hypotheses used to predict 
synergy may not necessarily apply to antagonism prediction, and vice 
versa. This further suggests a valuable path for approaches that inte-
grate different hypotheses for synergy, additivity and antagonism.
Even though the SynGen method, for which the data were 
originally generated, was highly effective in predicting compound 
synergy with higher sensitivity than other methods, its validation 
followed the more common procedure of prediction followed by 
evaluation against experimental data. However, despite the fact 
that SynGen is not based on machine learning methods that may 
be trained from experimental data, one cannot absolutely rule 
out potential overfitting. As such, direct comparison of SynGen’s 
performance to the community-submitted algorithms is not appropri-
ate and was deliberately avoided in this manuscript.
Our analysis also suggested that compounds exhibiting significant 
polypharmacology were enriched in synergistic pairs, whereas com-
pounds with targeted mechanisms were more likely antagonistic. This 
may be due to the increase in the probability of modulating specific 
synergistic genetic dependencies in the cell, when using polypharma-
cology compounds36,37. Thus, these experimental assays provide an 
initial basis to guide future development of rational methodologies 
for the study of synergistic compound combinations in ABC-DLBCL 
lymphomas, providing further insight about relevant pathways that 
may be exploited in synergy experiments.
Despite these advances, there is ample room for both algorithm and 
evaluation metric improvements. For instance, none of the methods 
achieved near-optimal predictive power. Indeed, even though this 
challenge shows that current methodologies can perform significantly 
better than chance, there is still a large gap between ground truth (PC-
index = 0.90) and the best prediction algorithms (PC index = 0.61). 
Methodological improvements are thus still required and could be 
achieved by several approaches, including (i) testing additional or 
more complex hypotheses about the mechanistic basis for compound 
synergy; (ii) generating larger perturbational profile data sets, for 
instance, using more concentrations and time points, to assess both 
early and late response to compound perturbation; (iii) exploring 
methodologies that better exploit the time-dependent nature of 
perturbational profiles; (iv) measuring complementary, context-
specific molecular profiles, such as proteomic and epigenomic 
landscapes, to perform cross-data modality integrative analyses; 
(v) further integrating different methods within a unified framework; 
and (vi) addressing synergy, additivity and antagonism using distinct 
conceptual frameworks and hypotheses.
Compound synergy and antagonism were assessed only at 
the IC20 concentration of individual compound, using the excess 
over Bliss additivity. In future challenges, however, synergy may need 
to be tested over a wider range of concentrations and using 
additional methodologies (e.g., isobolograms). Results from gold 
standard data and predictions from top teams suggests that while 
designing new synergy experiments, it is important to make a larger 
selection of mechanistically diverse small molecules (targeted and 
pleiotropic) to compensate for the small number of potentially syn-
ergistic pathways.
Our findings suggest that DREAM challenges can provide a 
valuable mechanism to accelerate the development of predictive 
models for combination therapy, by providing an objective platform 
for the identification of model strengths and limitations through 
unbiased evaluations of model performance.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Data provided to all participants in this challenge can 
be downloaded from http://www.the-dream-project.org/challenges/
nci-dream-drug-sensitivity-prediction-challenge. Raw CEL files for 
gene expression profiles are in GEO: GSE51068.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METhODS
Cell culture and compound treatment. The OCI-LY3 diffuse large B-cell 
lymphoma (DLBCL) cell line was obtained from University Health Network 
(Toronto, Canada) and was cultured under standard conditions (37 °C in 
humidified atmosphere, with 5% CO2) in IMDM supplemented with 10% FCS. 
Each compound was titrated in the OCI-LY3 cell line in a 20-point titration 
curve. Cell viability following compound treatment was determined using the 
CellTiter-Glo (Promega Corporation). An IC20 value for each compound was 
calculated by using Dose Response Fit and Calculate ECx components from 
the Pipeline Pilot Plate Data Analytics collection. For compounds in which 
more than 20% viability reduction could not be reached, a default concentra-
tion of 100 µM was used. For generation of GEPs, the OCI-LY3 cells were 
seeded in tissue culture–treated 96-well plates at a density of 50,000 cells per 
well (100 µl) and treated at the IC20 concentrations of each of the compounds 
at 24 h and 48 h. In the assay, three time points (6, 12 and 24 h) were analyzed 
for gene expression profiling. All profiles were generated in triplicate biological 
replicates except DMSO-treated samples which were hybridized in octuplicate 
as they were used as internal controls for each time point. To confirm viability 
data at each step, identical plates were produced and cell viability assessed 
using the CellTiter-Glo reagent (Promega Corporation).
Gene expression profiling. Total RNA was isolated with the Janus auto-
mated liquid handling system (PerkinElmer Inc.) using the RNAqueous-96 
Automated Kit (Ambion), quantified by NanoDrop 6000 spectrophotometer 
and quality checked by Agilent Bioanalyzer. 300 ng of each of the samples 
with RIN value >7 was converted to biotinylated cRNA with the Illumina 
TotalPrep-96 RNA Amplification Kit (Ambion) using a standard T7-based 
amplification protocol and hybridized on the Human Genome U219 96-Array 
Plate (Affymetrix). Hybridization, washing, staining and scanning of the array 
plates were performed on the GeneTitan Instrument (Affymetrix) according 
to the manufacturer’s protocols.
Experimental determination of synergy. For each compound, IC20 was deter-
mined assessed from 20-point titration curves (as described above) at 60 h 
following compound treatment by measuring cell viability and generating a 
dose-response curve. Each compound combination was then tested at the 
respective IC20 (or 100 µM) concentration of the individual compounds in 
five replicates. All compounds and combinations are diluted in DMSO, with a 
final DMSO concentration of 0.4%. Cells were placed at a density of 2,000 cells 
per well in 384-well plates, and compounds were added at 12-h intervals after 
seeding by compound transfers of serially diluted compounds. Assay plates 
were then incubated for 60 h followed by addition of 25 µl of CellTiter-Glo 
(Promega Corp.) at room temperature. Plates were read on the Envision 
(PerkinElmer Inc.) using enhanced luminescence protocol.
Data processing. All gene expression samples were quality controlled and 
normalized with the RMA normalization method using Bioconductor pack-
age in R. The baseline genetic profile of the OCI-LY3 cell line was obtained 
from reference18 and was processed using the CBS algorithm, as published47. 
The final segmentation file was filtered for any germline aberrations between 
1.74 and 2.3 and segments with less than eight markers. Segments with 
aberrations less than 1.74 or greater than 2.3 were assigned as deleted and 
amplified, respectively. 
Excess over Bliss as a measurement for synergy. The Bliss additivism 
(or Bliss independence) model48 predicts that if compound Dx and Dy, 
with experimentally measured fractional inhibitions fx and fy , have an 
additive effect, then the expected fractional inhibition, fxy , induced by their 
combination should be:
f f f f f f fxy x y x y x y= − − × − = + − ×1 1 1( ) ( )
Excess over Bliss is determined by computing the difference in fractional inhi-
bition induced by compound combination, fz, and the expected fractional 
inhibition, fxy
eob f fz xy= −  
A compound pair for which eob ≈ 0 has an additive behavior, whereas a 
compound pair with positive (or negative) eob values has synergistic 
(or antagonistic) behavior. We used propagation of errors using s.e.m. of 
fractional inhibitions to compute the s.e.m. of eob.
Resampled spearman correlation. To assess that the ranking of participants 
is not biased by our scoring methods, we used another independent approach 
to score all participants. This method assumed that the experimental mea-
surements of the mean excess over Bliss for a given compound pair is noisy, 
following a normal distribution, N(µ,σ), with mean, µ, equal to the mean EOB 
and s.d., σ, equal to the s.e.m. of excess over Bliss. For every compound pair, i, 
we randomly sample a possible measurement of the mean EOBi from the 
distribution associated with that compound pair N(µi,σi), resulting in a new 
sampled observed score for all compound pairs { , , }O O O1 2 91
rand rand rand
… . 
We compute a Spearman correlation between these new sampled EOB values 
and the predicted EOB ranks to generate scorrrand. We repeat this step 10,000 
times creating 10,000 different scorrrand and finally calculate an average over 
all 10,000 scorrrand to assign a final score, scorr, to each participant.
P-value estimation. We assessed the statistical significance of scores generated 
by both probabilistic c-index and resampled Spearman correlation methods by 
assigning a P-value to each score. To compute a P-value we generated 10,000 
random predictions and scored them independently using PC-index and scorr 
resulting in the generation of an empirical null distribution (PC-indexnull and 
scorrnull). We used this empirical null distribution to estimate P-values for 
each participant, which are calculated as the fraction of scores in the null 
distribution higher than the participant’s score
P PC− =
− ≥ −
−value
PC index PC index
index
null#( )
,10 000
P − = ≥value score scorrscorr null
#( )
,10 000
Leave-one-out test. To ensure that participant ranktings were robust, we cal-
culated a score for each participant by systematically removing one compound 
and considering 13 compounds for scoring and assigning them new ranks. 
This resulted in 14 different tests for each participant, each after removing 
one of the 14 compounds. In the end each team was assigned 14 ranks based 
on its performance using the remaining 13 compounds.
AUC and precision/sensitivity analyses. We estimated the significance of 
predicting synergistic and antagonistic compound pairs using the area under 
the receiver operating characteristic curve (AUC), which was called the 
sensitivity versus specificity analysis in the main text. To compute the AUC 
for synergistic predictions, first we sort the predictions of each participant 
from the most to the least synergistic (predicted list). Second, from the gold 
standard, we define the compound pairs that are synergistic and antagonistic. 
To identify such compound pairs we computed the signal to noise ratio (snr) of 
each compound pair, defined as the ratio of the mean excess over Bliss (EOB) 
over the s.e.m. of EOB. We defined any compound pair as synergistic if its 
mean EOB was positive and its snr is greater than 2, which yielded 16 syner-
gistic compound pairs. Similarly, a compound pair is defined to be antagonistic 
if its EOB is negative and its snr is greater than 2, yielding 36 antagonistic 
compound pairs. The rest of the pairs are considered to be additive. From the 
predicted list, we select the top i predictions and calculate the true positive 
rate (TPRi) and false-positive rate (FPRi). To estimate the TPRi and FPRi, we 
calculate the number of true positives (TPi), defined as the number of correct 
synergistic pairs in the top i predictions, the number of false positives (FPi), 
defined as number of false synergistic predictions in the top i predictions, the 
number of true negatives (TNi), defined as the number of correct nonsyner-
gistic compound pairs predicted below the top i predictions and the number 
of false negatives (FNi), defined as the number of synergistic compound pairs 
predicted below the top i predictions.
Finally, TPRi and FPRi are calculated as
TPR
TP
TP FN
FPR
FP
FP TNi
i
i i
i
i
i i
=
+
=
+
;
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We varied i from 1 to 91 and plotted the TPRi (or sensitivity) versus FPRi  
(or 1–specificity) to generate the receiver operating characteristic (ROC) 
curve. Finally, we calculated area under the ROC curve using a trapezoidal 
method to integrate the ROC curve. The AUC for antagonistic compound pairs 
is estimated by ranking predictions from the most to the least antagonistic and 
by selecting the true antagonistic compound pairs from the gold standard.
The precision/sensitivity analysis was performed as follows. After sorting 
the predictions of each participant from the most to the least synergistic, we 
compute the precision of synergistic predictions as the fraction of synergistic 
compound pairs in the top 16 predictions, that is
Precision(synergy) = TP16
16
Similarly, precision for antagonistic compound pairs was calculated by sorting 
the predictions of each participant from the most to least antagonistic and 
computing the fraction of antagonistic compound pairs in the top 36 predic-
tions. Sensitivity is defined as the number of TP (true positives) divided by 
the total number of positives, P (e.g., synergistic or antagonistic drug pairs). 
Because we selected the top P drug pairs to compute precision, our calculation 
of precision coincides with the evaluation of sensitivity.
Cross-validated ensemble models. To build ensemble models using predic-
tions from different methods, we averaged the rank for each compound pair 
predicted by all models being aggregated, and re-ranked the compound pairs 
according to the average rank. To evaluate the merits of aggregation, we used 
a model-selection assessment approach. We randomly divided all compound 
pairs into three subsets of equal sizes and used the first group, S1, for sort-
ing the models from the best to worst performance, the second group, S2, to 
estimate the number of models to combine to attain best performance, and, 
finally, the third group, S3, for an unbiased test of the individual or aggregate 
models. We repeated this process 1,000 times to evaluate the statistical sig-
nificance of the differences between aggregate versus individual performance. 
More precisely, in the ith split (where i is varied from 1 to 1,000), we compute 
the PC-index for each participant using the compound pairs in S1i, and based 
on their performance, create a team list T1i ordered from best to worst per-
forming teams. Next we aggregate the k best methods in T1i and use subset 
S2i to compute the PC-index (using the compound pairs in S2i), PC2ik, and 
vary k from 1 to 31. We identify k* such that PC2ik ≥ PC2ik for all k, giving us 
the number of participants whose aggregate gives the maximum PC-index 
(in S2i). Finally, using S3i, we compute the PC-index, PC3ik*, to determine the 
performance of top k* participants identified in the previous step but using the 
compound pairs in subset S3i. In this way, subsets S1 were used to determine 
which models to add cumulatively, subsets S2 were exclusively required for 
determining the optimal number of methods to achieve maximum perform-
ance and subsets S3 were solely used to estimate an unbiased performance of 
the aggregate that was eventually reported in Figure 4. For assessing a com-
parable single method performance, we chose the best performer determined 
on S1 and evaluated its performance on S3.
Area under the recall curve (AURC). For each compound, the area under the 
recall curve, AURC, is generated by first calculating the fraction of the 13 com-
binations that the chosen compound can participate in, contained in the top 
i compound pairs, ranked from the most synergistic to the most antagonistic 
pairs. We varied i from 1 to 91 and plotted that fraction versus i to generate 
the recall curve and finally calculated the area under the recall curve using the 
trapezoidal method. A high area under the recall curve is a predictor of the 
proclivity of a compound toward synergy, whereas a low area under the recall 
curve is a predictor toward antagonism.
Hanley-McNeil method. We estimated the statistical significance of the differ-
ence in performance by any two methods (i,j) by calculating the significance 
of the difference in the area under their ROC curve using the Hanley and 
McNeil method49. We calculated this significance separately for synergistic 
and antagonistic predictions. To estimate this significance for any method i, 
first we calculated the area under the ROC curve, Ai, using the trapezoidal 
method. Next we estimated the standard error, SEi, likely to be associated in 
the estimation of Ai
SE
A A n Q A n Q A
n ni
i i p i n i
p n
=
− + − − + − −( ) [(( )] )( ) ( )( )1 1 11 2 2 2
where
Q
A
A
Q
A
A
i
i
i
i
1 2
2
2
2
1
=
−
=
+
;
np = number of synergistic or antagonistic compound pairs and nn = 91 − np.
Finally we used the normal cumulative distribution function
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SE SE
i j
i j
to estimate the P-value where ‘erf ’ is the error function. Note that this 
procedure assumes independence between the predicted AUC, an assump-
tion that can be violated if there are hidden biases in the ordering of 
the compound pairs.
Compound-pair activity in the MCF7 and LNCAP cell lines. We tested 
the pairwise combinations of 71 compounds with a proteasome inhibitor 
MG 132 and a HDAC inhibitor Trichostatin A (a total of 142 combinations) 
in the MCF7 breast cancer cell line and the LNCAP prostate cell line by 
using a cell viability assay. For each pair of compounds, we performed 
16 experiments with four different dosages for each compound. To compute 
the synergy for each pair, we calculated the excess over Bliss score for each 
of the 16 experiments and took the average of 16 scores as the synergy score 
for the compound pair.
47. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation 
for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 
(2004).
48. Borisy, A.A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. 
Acad. Sci. USA 100, 7977–7982 (2003).
49. Hanley, J.A. & McNeil, B.J. The meaning and use of the area under a receiver 
operating characteristic (ROC) curve. Radiology 143, 29–36 (1982). 
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